CRBN and plasma cell myeloma: CFT7455 exhibits favorable physiochemical properties, pharmacokineticparameters, and good oral bioavailability in preclinical studies.14 CFT7455 is more potent and catalytically activethan other approved IMiDs and is currently in multiple clinical trialsfor treatment of multiple myeloma and relapsed/refractory non-Hodgkin’slymphoma.88 DKY709 (Table 3) as a CRBN binder induces the formationof the CRBN–DKY709–IKZF2 ternary complex.